Be a part of our medical cannabis research study!


Key Research Findings

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. (2006)
  • “In the first ever controlled trial of a CBM [Cannabis-based medicine] in RA, a significant analgesic effect was observed and disease activity was significantly suppressed following Sativex treatment.”
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.(2000)
  • “…these data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA [collagen-induced arthritis].”
  • “Its [CBD] efficacy when given orally renders it an attractive candidate for the treatment of RA. The experiments in the chronic CIA model show that prolonged treatment with CBD does not induce tolerance, a phenomenon often observed with cannabinoids”
Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis.
  • “…by abolishing early inflammation with prophylactic treatment, CBD attenuates [reduces] central sensitisation and neuropathic pain development in OA.”
  • Conclusion: “…CBD may be a safe therapeutic to treat OA pain locally as well as block the acute inflammatory flares that drive disease progression and joint neuropathy”
Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. (2016)
  • CBD administered by a transdermal gel reduced joint swelling, immune cell infiltration, synovial membrane thickening, and the synthesis of proinflammatory biomarkers in the Freund complete adjuvant model of inflammatory arthritis.”
Involvement of the endocannabinoid system in osteoarthritis pain. (2015)